Invesco Biotechnology & Genome ETF
PBE
81 hedge funds and large institutions have $80.7M invested in Invesco Biotechnology & Genome ETF in 2019 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 23 reducing their positions, and 3 closing their positions.
333% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 3
14% more funds holding
Funds holding: 71 → 81 (+10)
7% more capital invested
Capital invested by funds: $75.4M → $80.7M (+$5.21M)
0.88% less ownership
Funds ownership: 30.01% → 29.13% (-0.88%)
30% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 23
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$4.19M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.55M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$569K |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$448K |
| 5 |
CA
Calton & Associates
Tampa,
Florida
|
+$301K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Arlington Capital Management
Arlington Heights,
Illinois
|
-$12.8M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$316K |
| 3 |
Morgan Stanley
New York
|
-$244K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$244K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
-$139K |
PBE Hedge Fund Activity: Q1 2019 in Review
81 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q1 2019, worth a combined $80.7M — up 6.9% from $75.4M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new PBE positions and 3 closed out — a net gain of 10 holders — while 16 added to existing stakes and 23 trimmed.
The largest buyer was UBS Group, adding an estimated $4.19M. The largest seller was Arlington Capital Management, exiting entirely with an estimated $12.8M sold.
- 81 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q1 2019, up from 71 in Q4 2018.
- Funds reported $80.7M of Invesco Biotechnology & Genome ETF stock for Q1 2019, up 6.9% quarter-over-quarter.
- 13 funds opened new Invesco Biotechnology & Genome ETF positions in Q1 2019 and 3 closed out, a net change of +10 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q1 2019 was UBS Group, an estimated $4.19M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q1 2019 was Arlington Capital Management, an estimated $12.8M sold.
Based on aggregated 13F filings for Q1 2019.